SMTL ID : 3krr.1

Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.80 Å

Oligo State

monomer

Ligands

1 x DQX: 8-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-2-(1-piperidin-4-yl-1H-pyrazol-4-yl)quinoxaline(Non-covalent)

DQX.1: 22 residues within 4Å: Chain A: Q.16, L.18, G.19, K.20, G.21, G.24, V.26, A.43, K.45, V.74, M.92, E.93, Y.94, L.95, P.96, Y.97, G.98, R.143, N.144, L.146, G.156, D.157 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:V.26, A:A.43, A:V.74, A:L.146 Hydrogen bonds: A:L.95 Water bridges: A:K.45, A:Y.94, A:P.96, A:S.99 Salt bridges: A:D.157 Halogen bonds: A:N.144

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Baffert, F. et al., Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805. Mol.Cancer Ther. (2010)

Release Date

2010-07-21

Peptides

Tyrosine-protein kinase JAK2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase JAK2

Related Entries With Identical Sequence